Skip to main content
. 2020 Oct 23;44(6):2503–2516. doi: 10.3892/or.2020.7823

Figure 2.

Figure 2.

HNF1A-AS1 inhibits cell proliferation and cell cycle progression in laryngeal cancer cells. (A) Cell proliferation was assessed at 12, 24, 48 and 72 h using a Cell Counting Kit-8 assay. (B) Cell cycle distribution was analyzed by flow cytometry and (C) results of cell cycle analysis were analyzed statistically. (D) Western blotting was used to evaluate the protein expression levels of Cyclin D1 and PCNA following transfection of sh-NC, shRNA-1525 or shRNA-2048 into TU-686 cells and pLVX-control or pLVX-HNF1A-AS1 into TU-177 cells and (E) results of western blotting were analyzed statistically. Data are presented as the mean ± SD. All assays were performed in triplicate, and the values represent the mean of three independent experiments. For statistical analysis, ANOVA with Tukey's post hoc test was used to compare the sh-NC, shRNA-1525 and shRNA-2048 groups, and an unpaired t-test was used to compare the pLVX-control and pLVX-HNF1A-AS1 groups. *P<0.05, **P<0.01, ***P<0.001. HNF1A-AS1, hepatic nuclear factor 1 α antisense RNA 1; NC, negative control; PCNA, proliferating cell nuclear antigen; shRNA, short hairpin RNA.